EGFR and non-small cell lung carcinoma: Currently, EGFR-TKIs gefitinib and erlotinib are considered to be effective as first-line treatments for advanced NSCLC patients with EGFR-mutant (Inoue et al., 2013; Zhou et al., 2015).